eprintid: 10138479
rev_number: 18
eprint_status: archive
userid: 608
dir: disk0/10/13/84/79
datestamp: 2021-11-17 15:52:34
lastmod: 2022-10-22 06:10:45
status_changed: 2021-11-17 15:52:34
type: article
metadata_visibility: show
creators_name: Majumdar, A
creators_name: Verbeek, J
creators_name: Tsochatzis, EA
title: Non-alcoholic fatty liver disease: Current therapeutic options
ispublished: pub
subjects: RFH
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
divisions: G91
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and has an estimated global prevalence of 25%. NAFLD is found in up to 80% of people with obesity and over 60% of patients with diabetes. Cardiovascular disease is the main cause of mortality, followed by extra-hepatic cancers and then liver-specific complications of cirrhosis and hepatocellular carcinoma. Lifestyle modification remains the primary intervention in NAFLD. Weight loss achieved through dietary modification and exercise can lead to histologic improvement and reversal of metabolic complications. Current drug therapy is limited to pioglitazone and vitamin E; however, several agents are currently under phase III development. This review summarises the current treatment options in NAFLD.
date: 2021-12
date_type: published
publisher: ELSEVIER SCI LTD
official_url: https://doi.org/10.1016/j.coph.2021.09.007
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1896735
doi: 10.1016/j.coph.2021.09.007
lyricists_name: Tsochatzis, Emmanouil
lyricists_id: ETSOC40
actors_name: Tsochatzis, Emmanouil
actors_id: ETSOC40
actors_role: owner
full_text_status: public
publication: Current Opinion in Pharmacology
volume: 61
pagerange: 98-105
pages: 8
citation:        Majumdar, A;    Verbeek, J;    Tsochatzis, EA;      (2021)    Non-alcoholic fatty liver disease: Current therapeutic options.                   Current Opinion in Pharmacology , 61    pp. 98-105.    10.1016/j.coph.2021.09.007 <https://doi.org/10.1016/j.coph.2021.09.007>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10138479/3/Tsochatzis_Non-alcoholic%20fatty%20liver%20disease-%20Current%20therapeutic%20options_AAM.pdf